-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
5 Megatrend Plays Offering Big Payouts
Megatrend investments usually require years if not decades to play out, but these five particular stocks offer investors some sizable income for waiting.
If Not Amgen, Who’s Next in Line to Buy Onyx?
A few larger players could make attractive suitors for Onyx Pharmaceuticals and its cancer drugs, but the key is whether they'll trump an already frothy bid
Changing U.S. Demographics Mean a Decades-Long Healthcare Boom
The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs.
First-Half Sector Winners Offer a Hint of What’s to Come
Financials, healthcare and consumer discretionary stocks are sheltered from both China's economic weakness and rising bond yields, which bodes well for their second-half outlook.
3 Ways to Trade Diabetes Treatment
The treatment of diabetes continues to be a huge boon to drug companies. Here is a look att three potential stock picks for the space.
2 ‘A’-Rated Stocks for 2013’s Second Half
Staffing and human resources companies look poised to jump in the rest of 2013 and beyond, but pay special attention to those firms dealing in healthcare work forces.
The Beating Ain’t Done Yet: Monday’s IP Market Recap
Investors responded poorly to comments from The People's Bank of China and continued to let Fed statements fester Monday, continuing U.S. stocks' slide.
Seasonal Patterns Say to Buy Gold, Sell Semiconductors
Seasonal patterns aren't always reliable, but these charts show that it's nearing time to buy gold and take profits in semiconductors.
Arena, Vivus Look Good (And It Has Nothing to Do With the AMA)
The AMA has ruled to classify obesity more intensely -- as a "disease." But are ARNA and VVUS investors justified in being excited?
Now That Obesity Is Classified as a ‘Disease’ …
The American Medical Association's decision to classify obesity as a disease will impact physicians, patients, insurers and pharmaceutical companies.
So Your DNA Can’t Be Patented … Now What?
The Supreme Court recently ruled that identifying genes is not patentable ... which is both good and bad news for DNA-mapping companies.
It’s Hard to Win the Pharma News Game
Big news for three cancer-treatment drugs had virtually zero effect on the stocks. Here's why investors shouldn't have been surprised, and what they can learn.
Pharma, Tech Drive the Dow: Monday’s IP Market Recap
markets managed to start out the new month on a up note, as pharmaceuticals and technology companies shined during a broad-based rally
Expect a Slowdown, but the Bull Is Alive and Well
The trend is decidedly up and any correction should be viewed as a buying opportunity.
Study: New Bird Flu Resistant to Roche’s Tamiflu
Physicians in China have noted that some patients with bird flu are not responding to treatment with Tamiflu, the only known drug used to fight the infection.
AstraZeneca to Purchase Omthera
AstraZeneca will purchase Omertha, a make of fish-oil based pharmaceuticals as it continues to bolster its cardiovascular product lineup
3 Biopharma Runners With Fuel in the Tank
Biopharmaceutical stocks have been on a tear so far this year, but a few still have the pipeline power necessary to keep flying.
2 Stocks to Buy, 2 to Sell in Big Pharma
Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries.
Humana’s ‘Sell’ Signal May Be a Good Sign for Potential Buyers
Humana could pull back to the strong support zone between $72 and $75. Consider this an opportunity for potential buyers.
